Member Info for Haywain

I wont make share price predictions but both DL2 P1 (P4) and first paediatric patient are significant and value adding. P4 will prove or disprove that there is a therapeutic window ie that dose escalation does not dramatically impact the safety profile. The first paediatric patient will show that efficacy/safety profile holds or does not hold cross biology. I believe there will be a similar safety profile for P4 (for reasons I wont get into here) but that the kinetics will be faster (faster clearance of AML blasts). I believe also that with regard to paediatrics there (should be) similar safety and greater efficacy because of T-cell fitness being better in this population

Do you actually have a point somewhere in there 1/4/1 - you should make it more obvious - mostly the point is unintelligible to me - go for it - free floor

In short - no : still need to produce the CAR-T number of cells is not a driving factor for treatment cost - what you might say is this treatment may be a lot more expensive that FLT-3 CAR-T as these patients will need HSCT to consolidate which is estimated at between $500k-1M per patient int he US

Took a look at the anti-CD7 car-t phase 1 data reported at ASH: Brief summary and interpretation- CD7 is a T-Cell surface glycoprotein that is aberrantly expressed on up to a third of AML cells which makes it a good immunotherapeutic target in that subset. It isnt, however, core oncogenic driver of AML biology. Its more of a lineage marker that happens to be mis-expressed which means leukaemic cells can potentially survive by downregulating CD-7. While the results are generally encouraging for the concept of CAR-T therapy's use in the treatment of AML and MRD-ve results were reported, there also seemed to be on-target off tumour activity with the majority of the patients reporting cytopenias. This is important because the therapy could be envisaged as a dtrong debulker of AML blasts but may also lead to long term cytopenias and consolidation of effect would therefore require HSCT. the sentence being questioned around the starting dose in the other study simply means that they did not observe a dose dependent effect - escalation of starting cell count did not achieve higher numbers of expanded T-Cells and did not make a difference to the efficacy or saftey signals observed. This suggests a plateau effect/target - limited expansion - the CAR-T cells may be expanding to a biologically determined ceiling driven by antigen concentration rather than the input dose - dose escalation may not therefore meaningfully change the outcome.

I am flying - will take a look later

I have now seen it all - being reprimanded by pumpky for being childish and puerile - and pumpky actually on this occasion having the high ground- I am lost

Fantastic news - data is what we need and this pays for it. Dose escalation and paediatric dosing remove two of the last remaining question marks : is there a therapeutic window and does the effect translate across biology? my guess is - yes it will. Delighted that we will now find out.

Yes- plenty trailing this particular CAR-T

Treatments for paediatric AML and clinical research in paediatric AML is not unprecedented - what is unprecedented at least to my knowledge is FDA greenlighting it after 2 adult patients dosed for a CAR-T in this indication. - just doesn’t happen

KMT2A-r ALL is a lethal, stem/progenitor-driven leukaemia subtype, and FLT3 is often overexpressed/activated in it. So seeing KMT2A-r ALL appear in the roadmap isn’t random—it suggests Hemogenyx thinks their FLT3 targeting is hitting the right biology for deep, durable disease control not just clearing bulk blasts ie active at the FLT3 +ve stems cells selectively/progenitor cell level - if that’s the case then these are the source of relapse for both AML and this particular type of ALL - it strengthens the curative argument.

It is precisely the outcome of the MSK trial that gives me confidence we are seeing something different with HG-CT-01. In the referenced study patients experienced on-target off-tumour effects leading to prolonged cytopenias, leaving them severely immunocompromised. As a result although 3/5 patients initially responded- they subsequently either succumbed to infection or relapsed, with two doing so within two months of treatment. All requiring HSCT to consolidate any benefit. If a similar safety profile were emerging with HG-CT-01 the programme would not have progressed as it has. The FDA’s decision to green-light paediatric dosing after just two adult patients together with DSMB approval for dose escalation following several months of follow-up would not occur in the presence of severe CRS and cytopenias. I have no doubt that detailed data will be disclosed in due course, these regulatory and safety signals suggest HG-CT-01 may be behaving in a way not previously seen with CAR-T (or any other therapy) in AML. With Patient 1 approaching 12 months post-treatment in February, clarity is not far away. Happy New Year — and here’s hoping 2026 looks very different for Hemogenyx than years past.

Not sure - because Greek for Christ/ Christos starts with an X?

😂

Alde - I get it you don’t want to invest in hemogenyx - fine so why are you here again? I suggest you should go back to your favourite company with the stonking clinical phase 1b progress and results announced yesterday you should be delighted- I mean 2/30 patients partial response is a really good start.

I don’t know what you are getting at Joe - but do I hold shares - Yes : do I trade -No - do I believe I will receive a return for my investment - yes ; do I belive that patients will benefit from Hg-Ct-1 treatment - yes : so long as I believe that is the case then I hold my shares - simple

Ok - the only thing that has been wrong is assumptions around timing and how certain mal actors would use gaps in news along with knowledge about warrants being sold to create a mechanical advantage to allow shorting to negatively impact the share price. My point is I am not a trader - I care about the science and that has not changed but strengthened and continues to strengthen as time goes on. Whether I am right or wrong will be judged in the data that is released not what the share price does in the interim.

All i said was to come back to me in a few weeks time when Hemogenyx has released efficacy and applied for breakthrough designation see who wins the "war" - what that is too much to handle is it ?

Good job that the main market has more love for feelings then.

“You can not be serious” Alright John McEnroe keep your hair on- clinical CAR-T with “signs of efficacy” - in FLT3+ r/r AML and safe as a monotherapy? that profile is unheard of & unprecedented if it continues a early phase 1 licensing/acquisition is probable IMO

About time really some I know we are not listed on AIM but same principal applies - some of the behaviours on here have been disgusting